Abstract. While a number of genetic and environmental risk factors for coronary heart disease (CHD) have been identified, the list of potential risk factors remains long. One candidate is dimethylarginine dimethylaminohydrolase (DDAH2), which is known to be polymorphic in humans. The gene product indirectly increases the endogenous production of nitric oxide, an anti-atherogenic molecule. Therefore, alterations in DDAH2 activity may indirectly result in an increased risk of CHD. We studied allele and genotype distributions for two polymorphic loci of DDAH2, rs805305 and rs2272592, in 180 patients with CHD and 180 healthy controls. Disease history and other clinical data were recorded. Polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) was used to determine the genotype at rs805305, and ligase detection reaction (LDR) was used to determine the genotype at rs2272592. Systolic blood pressure and blood triglyceride and glucose levels were higher, and history of hypertension, diabetes, smoking and alcohol use was more common in the patients with CHD (P<0.05). However, the genotype and allele frequencies at the two polymorphic loci of DDAH2 were not statistically different between the two groups. Therefore, no association was observed between the DDAH2 polymorphisms at rs805305 and rs2272592 and CHD.
Introduction
Coronary heart disease (CHD) occurs with high incidence and results in many deaths from ischemic events (1) . CHD may be attributed to the interaction of genetic and environmental factors (2) . CHD pathogenesis proceeds when vascular endothelial injury leads to blood lipid deposition in the smooth endarterium, causing the formation of white atherosclerotic plaques. These plaques continue to grow, forming a thrombus that may either block blood flow directly or dislodge and travel through the circulation. These actions may result in myocardial infarction or stroke.
While a number of genetic and environmental factors that promote CHD have been identified, relatively few factors are known to reduce the risk of the disease. One, nitric oxide (NO), is considered to be an endogenous anti-atherosclerotic plaque factor (3) . NO is produced in the body by nitric oxide synthase (NOS) (4, 5) . NOS activity, and therefore NO synthesis, may be reduced by an endogenous competitive inhibitor, asymmetric dimethylarginine (ADMA) (6) . ADMA, however, becomes inactivated via hydrolysis by dimethylarginine dimethylaminohydrolases (DDAHs); DDAH has two subtypes, including DDAH2 which is mainly expressed in vascular endothelial cells (7) . Changes in DDAH activity or expression may affect the synthesis of NO by affecting ADMA levels (8) . DDAH activity and/or expression may be affected by polymorphisms within the gene; therefore, polymorphisms in DDAH may be associated with CHD.
Two polymorphisms in DDAH have been identified: rs805305 and rs2272592 (9, 10) . In the present study, we determined the frequency of these polymorphisms in CHD patients and healthy individuals to investigate whether these polymorphisms may predispose an individual to CHD. 
Materials and methods

Participants
DDAH2 genotype identification at the rs805305 locus.
The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to genotype DDAH2 at the rs805305 locus. A 5-ml sample of venous blood was taken from each patient and genomic DNA was isolated from each sample by phenol-chloroform-isoamyl alcohol extraction. The target fragment that potentially contained the polymorphism was amplified by PCR using the following primers (Takara, Dalian, China): forward, 5'-CCTTCTCGTTCGGGTATTCAG-3'; and reverse, 5'-TCCAGACCTTCCGCTCCT-3'. The reaction mix included 2 µl genomic DNA, 2.5 µl 10X PCR buffer (Promega, Madison, WI, USA), 1.5 µl 25 mM dNTP (Promega), 0.25 µl 2.5 U/ml Taq DNA polymerase (Promega), 1.5 µl 25 mM MgCl 2 (Promega), 0.5 µl forward primer (100 pmol/l), 0.5 µl reverse primer (100 pmol/l) and water (to a final volume of 25 µl). The thermal cycling conditions were as follows: pre-denaturation at 94˚C for 5 min; 30 cycles of denaturation at 94˚C for 60 sec, annealing at 58˚C for 60 sec and extension at 72˚C for 60 sec; and elongation at 72˚C for 5 min. The amplified PCR product (2 µl) was digested with 2 µl SmaI (Promega) in 2 µl 10X buffer (with deionized water to a final volume of 20 µl) in a 30˚C water bath for 4 h. The reaction product (5 µl) was separated by agarose gel electrophoresis. The expected band sizes are as follows (see Fig. 1 
Results
Comparison of medical history and biochemical indexes between the CHD patients and healthy individuals.
Analysis of the medical histories and biochemical indices between the patients with CHD and the healthy individuals revealed higher systolic blood pressure and blood triglyceride and glucose levels in the CHD patients than in the control group; these differences were statistically significant (P<0.05). Additionally, the percentages of patients with CHD who had a history of hypertension, diabetes, smoking or alcohol use were 56.11, 27.22, 47.78 and 52.78%, respectively. Each of these percentages was significantly higher than the corresponding value in the control group (P<0.05; Table I ). 
DDAH2 genotype frequency does not differ at the rs805305 locus.
The allele frequencies for the polymorphisms in DDAH2 at rs805305 were in Hardy-Weinberg equilibrium for the experimental and control groups (P>0.05). The genotype frequencies of GG, CG and CC were, respectively, 17.78, 65.56 and 16.67% in patients with CHD and 23.33, 55.56 and 21.11% in the control group; these distributions were not significantly different. The frequencies of G and C alleles were 50.56 and 49.44% in the experimental group and 51.11 and 48.89%, respectively, in the control group; again, these distributions were not significantly different (Table II) .
DDAH2 genotype does not differ at the rs2272592 locus.
The allele frequencies for the polymorphisms in DDAH2 at rs2272592 were in Hardy-Weinberg equilibrium for the experimental and control groups (P>0.05). The genotype frequencies of GG, GA and AA were 63.89, 33.89 and 2.22%, respectively, in the experimental group and 71.11, 27.22 and 1.67%, respectively, in the control group; these differences were not statistically significant. The frequencies of G and A alleles were 81.94 and 18.06%, respectively, in the experimental group and 84.72 and 15.28%, respectively, in the control group; again, these distributions were not statistically different (Table III) .
Discussion
Studies have shown that NO, a fat-soluble molecule, is able to rapidly diffuse into target cells, including vascular smooth muscle cells and neurons; additionally, NO is considered to be a messenger molecule with wider effects in the body (12) . NO is produced by endothelial cells and it diffuses into and relaxes vascular smooth muscle cells, causing hemangiectasis and blood pressure decline (13) . Furthermore, NO is able to inhibit smooth muscle cell proliferation by preventing platelet aggregation and reducing the formation and growth of atherosclerotic plaques. Endogenous NO is mainly generated via L-arginine conversion and a reaction catalyzed by NOS (14) ; defects in the metabolism of NO are considered to contribute to the pathogenesis of CHD.
Due to the ability of the endogenous molecule ADMA to inhibit NOS activity, it is very important in the pathogenesis of CHD (15) . However, since ADMA is hydrolyzed by DDAH to L-citrulline and dimethylamine in the body, it may lose its activity. DDAH, therefore, may effectively reduce the concentration of ADMA and increase the activity of NOS, thereby increasing NO synthesis. DDAH has two subtypes, DDAH1, which is mainly expressed in the nervous system, and DDAH2, which is mainly expressed in the cardiovascular system (16) . Gene knockouts have shown that a lack of DDAH expression in DDAH null mice results in an increased plasma ADMA concentration and reduced NO concentration, along with significantly increased blood pressure (17) . Therefore, individuals with reduced DDAH2 activity may carry a CHD risk factor.
The results of this study demonstrated, as expected, that BMI and blood triglyceride and glucose levels were all significantly higher in patients with CHD than in healthy individuals; similarly, histories of hypertension, diabetes, smoking or alcohol use were all more common among CHD patients. Indeed, hypertension, diabetes, smoking and alcohol use are known risk factors for CHD (18) .
However, although DDAH2 has generated interest as a potential risk factor for CHD, our analysis of two polymorphic loci in the DDAH2 gene did not uncover any differences in the distribution of alleles between healthy individuals and patients with CHD. Therefore, polymorphism at rs805305 or rs2272592 is not associated with CHD. Notably, a study by Jones et al (19) suggested that polymorphisms in the DDAH2 promoter affected DDAH2 expression in vascular endothelial cells and that polymorphism at the DDAH2 promoter 871 locus was correlated with changes in ADMA levels in the body. However, Maas et al (10) reported no correlation between polymorphisms at the rs805304 or rs805305 loci of the DDAH2 promoter and CHD, supporting our findings. The differences between our findings and those reported by Jones et al may result from two characteristics of our study: a smaller sample size and the possibility that participants in our study may not accurately represent the population distribution of the region.
In conclusion, the results from this study reveal that hypertension, diabetes, smoking and alcohol consumption are all risk factors for CHD, but polymorphisms in DDAH2 at rs805305 and rs2272592 are not associated with CHD.
